Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
about
Tumor dormancy: potential therapeutic target in tumor recurrence and metastasis preventionContemporary Management of Prostate CancerOptimal management of prostate cancer with lethal biology--state-of-the-art local therapyGrowth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G1 Arrest/S Phase Delay and Inhibition of Apoptosis During Chemotherapy in Bone MarrowA novel miRNA-based predictive model for biochemical failure following post-prostatectomy salvage radiation therapyA tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapyDetermining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens.Radiotherapy after radical prostatectomy: treatment recommendations differ between urologists and radiation oncologists.Risk stratification in the hormonal treatment of patients with prostate cancermiR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer.The Metabolic Syndrome and Biochemical Recurrence following Radical Prostatectomy.Adjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer.Postoperative radiotherapy after radical prostatectomy: indications and open questionsTiming of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy.Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome.Stereotactic body radiation therapy for prostate cancer patients with old age or medical comorbidity: a 5-year follow-up of an investigational study.When Palliative Treatment Achieves More Than Palliation: Instances of Long-term Survival after Palliative RadiotherapyUsing prostate-specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer.Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer.Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era.Predictive factors for biochemical recurrence in radical prostatectomy patientsCan we stop prostate specific antigen testing 10 years after radical prostatectomy?Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials.Development and validation of a 32-gene prognostic index for prostate cancer progression.Is lymphovascular invasion a powerful predictor for biochemical recurrence in pT3 N0 prostate cancer? Results from the K-CaP databaseSalvage radiotherapy after radical prostatectomy.Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone?Clinical significance and treatment of biochemical recurrence after definitive therapy for localized prostate cancer.Dynamic prediction of metastases after radical prostatectomy for prostate cancer.Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models.Dormancy in solid tumors: implications for prostate cancer.Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence.The biology and clinical implications of prostate cancer dormancy and metastasis.Contrasting roles of the ABCG2 Q141K variant in prostate cancer.Outcome of radical prostatectomy in primary circulating prostate cell negative prostate cancer.Identification of enhancer of zeste homolog 2 expression in peripheral circulating tumor cells in metastatic prostate cancer patients: a preliminary study.Androgen receptor profiling predicts prostate cancer outcome.Prostate cancer that is within 0.1 mm of the surgical margin of a radical prostatectomy predicts greater likelihood of recurrence.Factors determining biochemical recurrence in low-risk prostate cancer patients who underwent radical prostatectomy.
P2860
Q21195742-4F1E8582-2B88-4E00-A89A-7D538192675CQ26767456-DCF5DA42-8645-4614-976D-603E494E77E4Q26801188-42B76899-30E1-4236-B7CE-A51221BFA5A1Q27853382-E5E88DEB-9CAD-4B82-990D-265951A6687BQ28543958-961376CD-C56D-4ECE-B95B-C382DA3B40A8Q33375063-216B45E5-5690-4997-80A9-EA16DD095D0FQ34756267-4103C6BD-C1C9-4F63-955C-2BC436C8883CQ35041485-59B70D55-19D4-4238-9632-EEBACC4D5695Q35076189-F92F8C25-CF6B-411E-844E-FD9E2F6AE2CDQ35195342-BA940A59-EDDA-4E60-AB5A-9CFABBBD948AQ35390159-2BD2997D-4939-45DE-A4B5-E67A1F713705Q35608929-03A3DCCF-ECF7-47FD-8EED-2C61BDF1F03AQ35863963-A37D73C1-5B02-41D0-8E59-3E63B9E2C837Q35946099-D73EF366-4291-4740-876A-4860A32AFA9EQ36023678-B536256E-B237-4FAC-AC39-7524EBC88F0AQ36140754-860FAEC7-6E2A-4FAE-BA39-E7FB7A780FC2Q36154146-9B6F3CD1-52D6-4498-A289-4CB17E2AE418Q36336093-3E19B613-9AB4-4EED-9F86-1F9583556A54Q36432832-03C101C6-008B-41DE-AC32-E05C46D5985DQ36455680-FB7A4DC7-689A-49CC-974C-1CDF5606A5D9Q36510172-57125F97-E40A-4FA8-B50B-FA347FDD3E9CQ36547490-42CF03E3-2F0B-443E-8E94-2644843D3CFEQ36571154-4DBC1909-5DF3-42C4-9E21-CADDD95B23DAQ36754806-D02E9E70-A79E-44F8-A351-7F6968D86702Q36762398-229B9055-1B0B-4C21-B9FD-03C04FD0097CQ36870722-4D751EF8-2D14-47FE-BB1C-DC70BC3B74EFQ37216103-72CB599E-3854-4E79-A033-65F569288307Q37366271-A287EFB8-A185-4F36-A2C1-AC8AE3E95453Q37460247-80E6159E-D8E9-460F-A2B3-9F5BA2155478Q37637096-44A04B7F-06DF-498D-AC59-3ED432EA7D1EQ37694857-1A4A163F-2747-47E1-AFE1-23CDE2F55EFBQ38101246-EF2FF281-5A73-4237-A7D9-3955A7F3BFBBQ38263525-E5BBF21F-3081-496B-9044-1886A75352B4Q38613304-2F99C8B9-8443-4C6E-8555-E4CEAE6AC63FQ38903771-9E8B67CE-5C3D-4416-A747-9637010377D5Q39408135-CE6E76EE-DA1C-408A-8B0C-A6BE70B8918FQ40030927-EF9259A7-FD4B-43E0-9DB2-F17CA4BCE441Q40493333-19A515C4-AE80-4242-BB15-3F7036FB1F4BQ40574917-6923308B-1362-4F1B-998C-8A42DF8583CBQ40586543-62846C5C-90AA-48F1-B445-AA0863E6BAF4
P2860
Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Long-term hazard of progressio ...... hemical failure after 5 years.
@en
Long-term hazard of progressio ...... hemical failure after 5 years.
@nl
type
label
Long-term hazard of progressio ...... hemical failure after 5 years.
@en
Long-term hazard of progressio ...... hemical failure after 5 years.
@nl
prefLabel
Long-term hazard of progressio ...... hemical failure after 5 years.
@en
Long-term hazard of progressio ...... hemical failure after 5 years.
@nl
P2093
P1476
Long-term hazard of progressio ...... hemical failure after 5 years.
@en
P2093
P304
P356
10.1097/00005392-200007000-00023
P407
P577
2000-07-01T00:00:00Z